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Summary
Mutations or duplications in MECP2 cause Rett and
Rett-like syndromes, neurodevelopmental disorders
characterized by mental retardation, motor dysfunc-
tion, and autistic behaviors. MeCP2 is expressed in
many mammalian tissues and functions as a global
repressor of transcription; however, the molecular
mechanisms by which MeCP2 dysfunction leads to
the neural-specific phenotypes of RTT remain poorly
understood. Here, we show that neuronal activity and
subsequent calcium influx trigger the de novo phos-
phorylation of MeCP2 at serine 421 (S421) by a CaM-
KII-dependent mechanism. MeCP2 S421 phosphoryla-
tion is induced selectively in the brain in response to
physiological stimuli. Significantly, we find that S421
phosphorylation controls the ability of MeCP2 to regu-
late dendritic patterning, spine morphogenesis, and
the activity-dependent induction ofBdnf transcription.
These findings suggest that, by triggering MeCP2
phosphorylation, neuronal activity regulates a program
of gene expression that mediates nervous system
maturation and that disruption of this process in indi-
viduals with mutations in MeCP2 may underlie the
neural-specific pathology of RTT.
Introduction
Rett Syndrome (RTT) is an X-linked neurological disor-
der and a leading cause of mental retardation in females.
Classical RTT is characterized by relatively normal
development through the first 6–18 months of life, fol-
lowed by an abrupt neurodevelopmental regression
and stagnation that may result in loss of acquired skills
such as purposeful movement and speech, deceleration
of head growth, irregular breathing, stereotypical hand
wringing, and the emergence of autistic behaviors (Hag-
berg et al., 1983; Moretti and Zoghbi, 2006; Rett, 1966).
The symptoms of RTT appear during early childhood
when sensory experience is driving the synaptic reorga-
nization required for the emergence of appropriately
functioning circuits in the mature brain. This observation
raised the hypothesis that the underlying cause of
*Correspondence: michael.greenberg@childrens.harvard.edu
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possibly resulting from abnormal experience-depen-
dent synaptic maturation, refinement, and/or mainte-
nance (Zoghbi, 2003).
The majority of RTT cases are caused by mutations
in the methyl-CpG-binding protein 2 (MECP2) gene
(Amir et al., 1999). MeCP2 is a member of the family of
methyl-CpG-binding domain (MBD) proteins that func-
tion as long-range transcriptional repressors that medi-
ate developmental silencing through binding to methyl-
ated DNA (Klose and Bird, 2006; Lewis et al., 1992). In
addition to its amino-terminal MBD, MeCP2 contains
a transcriptional-repressor domain (TRD) and a C termi-
nus that facilitates binding to methylated DNA (Chandler
et al., 1999; Kriaucionis and Bird, 2003). The mutations
found in RTT span the entire MeCP2 protein and include
missense, nonsense, insertion, deletion, and splice-site
variations (Bienvenu and Chelly, 2006; Kriaucionis and
Bird, 2003). Recently, reports of duplications of the en-
tire MECP2 locus in some individuals with a RTT-like
phenotype suggest that overexpression of MeCP2 also
leads to Rett Syndrome (Ariani et al., 2004; Lugtenberg
et al., 2006; Meins et al., 2005; Van Esch et al., 2005).
Like other MBD family proteins, MeCP2 is expressed in
many somatic tissues. How disruption of this ubiqui-
tously expressed protein leads to a predominantly neu-
rological phenotype remains a central unresolved issue
in the RTT field. One hint may lie in the fact that MeCP2
protein levels increase as neurons mature (Zoghbi,
2003). The high level of MeCP2 protein in mature neurons
is consistent with a possible role for MeCP2 in synaptic
processes.
Knockout mouse models with disrupted MeCP2 func-
tion mimic many key clinical features of RTT, including
normal early postnatal life followed by developmental re-
gression that results in motor impairment, irregular
breathing, hindlimb clasping, and early mortality (Chen
et al., 2001; Guy et al., 2001; Shahbazian et al., 2002). In
addition, transgenic mice overexpressing wild-type
MeCP2 protein also develop a RTT-like phenotype, sug-
gesting that a precise level of MeCP2 expression is crit-
ical for proper brain development (Collins et al., 2004;
Luikenhuis et al., 2004). Importantly, the conditional de-
letion of Mecp2 in postmitotic neurons recapitulates
many of the phenotypes seen in the Mecp2 total null
mouse (Chen et al., 2001; Guy et al., 2001), indicating
that RTT is due to a specific defect in MeCP2 function
in mature neurons.
Further supporting a role for MeCP2 in mature synap-
tic function and plasticity, Mecp2 null mice exhibit ab-
normalities in dendritic arborization (Chen et al., 2001;
Kishi and Macklis, 2004), basal synaptic transmission
(Moretti et al., 2006), presynaptic function (Asaka et al.,
2006; Moretti et al., 2006; Nelson et al., 2006), excitatory
synaptic plasticity (Asaka et al., 2006; Moretti et al.,
2006), and hippocampal and amygdalar learning (Mor-
etti et al., 2006; Pelka et al., 2006). In addition, Mecp2
mutant mice exhibit reduced spontaneous cortical
activity due to an imbalance between excitatory and
inhibitory circuitry in the cortex (Dani et al., 2005).
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viduals and Mecp2 mutant mice—defects in dendritic
branching, spine density, synaptic plasticity, learning
and memory, and the maturation of inhibitory circuits—
involve processes known to be influenced by experi-
ence-dependent neuronal activity (Katz and Shatz, 1996).
However, the molecular mechanisms by which MeCP2
dysfunction leads to these physiological and cellular
defects and the relationship between MeCP2 and
experience-dependent synaptic development remain
undefined.
We recently found that membrane depolarization of
neurons leads to phosphorylation of MeCP2, which
correlates with the transcriptional induction of an activ-
ity-regulated gene, Bdnf (Chen et al., 2003). These find-
ings, together with those of other groups (Ballas et al.,
2005; Martinowich et al., 2003), suggested that dynamic
regulation of MeCP2 by calcium influx may play a pivotal
role in regulating specific programs of activity-depen-
dent gene transcription that are important for nervous
system function. In the present study, we investigated
the significance of the calcium-dependent phosphoryla-
tion of MeCP2 for nervous system maturation and RTT.
We find that phosphorylation of MeCP2 at a specific
amino acid residue, S421, occurs selectively in the ner-
vous system in response to neuronal activity. Mutation
of MeCP2 at S421 blocks the ability of MeCP2 to restrict
dendritic growth, spine maturation, and activate cal-
cium-dependent Bdnf transcription in an in vitro overex-
pression model of RTT. These findings suggest that, by
triggering MeCP2 phosphorylation, neuronal activity reg-
ulates a program of gene expression that mediates neu-
ronal connectivity in the nervous system. The disruption
of this process in individuals with mutations in MeCP2
may underlie the neural-specific pathology of RTT.
Results
Identification of S421 as a Site Required
for Membrane Depolarization-Induced
Phosphorylation of MeCP2
We have previously shown that membrane depolariza-
tion of neurons by exposure to elevated levels of extra-
cellular potassium leads to the production of a slow-
migrating species of MeCP2 as detected on a denaturing
SDS-polyacrylamide gel (SDS-PAGE; Figure 1A, left).
This slow-migrating form of MeCP2 disappears when
extracts from membrane-depolarized neurons are
treated with alkaline phosphatase (Figure 1A, right), sug-
gesting that phosphorylation of MeCP2 may slow its
migration on an SDS-PAGE gel. The slow-migrating
form of MeCP2 exhibits reduced binding to methylated
DNA, and its presence correlates with the induction of
Bdnf promoter IV transcription in cortical cultures (see
Figure 5 legend forBdnfpromoter nomenclature), raising
the possibility that the phosphorylation of MeCP2
may inactivate the repressor function of MeCP2 (Chen
et al., 2003). However, it remained to be determined
whether phosphorylation, or another modification, regu-
lates MeCP2 function in membrane-depolarized neurons
and whether these modifications are relevant to the
etiology of RTT.
To address these issues, we sought to identify the
amino acid residues on MeCP2 that become newlyphosphorylated upon membrane depolarization of corti-
cal neurons. We used tandem mass spectrometry to
identify phosphorylation sites present on endogenous
MeCP2 protein purified from P15 rat brain nuclear
extracts (Figure 1B), as well as MeCP2 expressed in
HEK293T cells (data not shown). Taken together, the
mass spectrometry analyses revealed the presence of
three major sites of phosphorylation—serine 80 (S80),
serine 229 (S229), and serine 421 (S421) (Figure 1C).
We next generated nonphosphorylatable mutant forms
of MeCP2 to determine if the phosphorylation events
identified by mass spectrometry were required for the
generation of the slowly migrating species of MeCP2
in response to membrane depolarization. FLAG-tagged
wild-type MeCP2 or MeCP2 constructs bearing various
serine to alanine mutations were transfected into corti-
cal neurons, and the tagged MeCP2 was detected by
western blot with an antibody directed against the
FLAG epitope. Whereas mutation of S80 and S229 of
FLAG-MeCP2 to alanine did not affect the production
of the slow-migrating species of MeCP2 in response to
membrane depolarization, mutation of S421 to alanine
(S421A) resulted in the loss of the activity-dependent
MeCP2 mobility shift (Figure 1D). Moreover, mutation
of 17 additional MeCP2 serine or threonine residues pre-
dicted by the Scansite program (http://scansite.mit.edu)
to be phosphorylated (S13, S86, S113, S164, S178,
S216, S229, S341, S350, S357, S360, S385, S399,
T308, T311, T443, T477), either individually or in combi-
nations, did not affect the production of the slow-mi-
grating form of MeCP2 (data not shown). Thus, S421 is
required for the generation of the slow-migrating form
of MeCP2 in membrane-depolarized neurons, suggest-
ing that membrane depolarization triggers the phos-
phorylation of MeCP2 at S421. Although we cannot
exclude the possibility that membrane depolarization
may concomitantly trigger the phosphorylation or de-
phosphorylation of MeCP2 at other sites, the phosphor-
ylation status of these sites does not appear to affect
the mobility of MeCP2 on an SDS-PAGE gel.
MeCP2 Is Phosphorylated at S421 in Response
to Neuronal Activity
To directly assess whether membrane depolarization in-
duces the phosphorylation of MeCP2 at S421, we raised
an anti-MeCP2 S421 phospho-site-specific antibody
(anti-MeCP2 pS421) and used the antibody to assess
the phosphorylation status of MeCP2 under various
conditions of neuronal stimulation in culture and in vivo.
We first tested affinity-purified fractions of sera from
rabbits immunized with a synthetic phosphopeptide
containing phosphorylated MeCP2 S421 for their ability
to recognize the nonphosphorylated and S421-phos-
phorylated forms of MeCP2. Western blotting of FLAG
immunoprecipitates from cortical neurons expressing
FLAG-tagged MeCP2 indicated that the anti-MeCP2
pS421 antibody specifically recognizes a band corre-
sponding to the slow-migrating species of MeCP2 in
membrane-depolarized neurons (Figure 1E). However,
the anti-MeCP2 pS421 antibody failed to recognize a
mutant version of FLAG-MeCP2 in which S421 was
replaced with an alanine (S421A) in either untreated or
membrane-depolarized neurons (Figure 1E). Further-
more, the anti-MeCP2 pS421 antibody effectively
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257Figure 1. Identification of MeCP2 S421 as
a Site of Membrane Depolarization-Induced
Phosphorylation
(A) Antitotal MeCP2 western blots of whole-
cell lysates (lanes 1–3) or nuclear extracts
treated with alkaline phosphatase (lanes 5–
7) prepared from E18 + 5 DIV dissociated rat
cortical neurons harvested at the indicated
times following 55 mM KCl stimulation. The
arrow indicates the slow-migrating form of
MeCP2 induced in response to membrane
depolarization. AP: Nuclear extracts were
treated with 2, 4, or 8 U of calf intestinal alka-
line phosphatase for 30 min at 37C prior to
SDS-PAGE separation. Note: MeCP2 runs at
approximately 75 kDa on an 8% SDS-PAGE
gel. All protein samples in this study were sep-
arated on an 8% gel unless otherwise noted.
(B) Coomassie blue staining of MeCP2 pro-
tein purified from rat brain nuclear extract.
Both bands were excised and subjected to
tandem MS/MS sequencing for identification
of phosphorylation sites.
(C) A schematic of MeCP2 illustrating the
positions of phosphorylation sites relative
to the methyl-CpG-binding domain (MBD),
nuclear localization signal (NLS), and the
transcriptional repression domain (TRD).
(D) Identification of S421 as a residue re-
quired for membrane depolarization-induced
phosphorylation of MeCP2. FLAG-tagged
wild-type or S421A MeCP2 was transfected
into E18 + 2 DIV cortical neurons. Two days
later, extracts were prepared from untreated
neurons or neurons membrane depolarized
for 60 min and subjected to western blotting
with the anti-FLAG antibody.
(E) A phosphospecific antibody detects
phosphorylation of MeCP2 at S421. FLAG
immunoprecipitates from E18 + 5 DIV cortical
neurons transfected with FLAG-tagged wild-
type or S421A MeCP2 were immunoblotted
with antitotal MeCP2 or anti-MeCP2 pS421 antibodies. The anti-MeCP2 pS421 antibody recognizes a band at a position corresponding to
that of the slow-migrating species of MeCP2.
(F) Membrane depolarization triggers the phosphorylation of MeCP2 at S421. Antitotal MeCP2 and anti-MeCP2 pS421 western blots of
nuclear extracts prepared from unstimulated or membrane-depolarized E18 + 5 DIV cortical neurons, either untreated (control) or incubated
with alkaline phosphatase for 30 min at 37C (AP). Unlike other experiments, cultures were not treated with TTX prior to stimulation in this
experiment.
(G) The anti-MeCP2 pS421 antibody specifically recognizes MeCP2. Brain lysates from C57BL/6 wild-type Mecp2+/+, heterozygous Mecp22/+,
or Mecp22/y null mice were probed with anti-MeCP2 pS421 or anti-actin antibodies.recognizes endogenous MeCP2 in extracts from mem-
brane-depolarized neurons (Figure 1F), but not in
extracts from unstimulated neurons (Figure 1F, left),
membrane-depolarized neurons treated with alkaline
phosphatase (Figure 1F, right) or brain extracts from
Mecp22/y null mice (Figure 1G). Together, these findings
indicate that the anti-MeCP2 pS421 antibody specifically
recognizes the S421-phosphorylated form of MeCP2. In
addition, these results demonstrate that phosphoryla-
tion of MeCP2 at S421 is an inducible event that is trig-
gered by membrane depolarization in cultured neurons.
Neurotransmitter Release at Synapses and
Neurotrophin Stimulation Both Trigger MeCP2
S421 Phosphorylation
Although MeCP2 has been thought to function primarily
as a stable, long-range transcriptional silencer, the find-
ing that MeCP2 undergoes dynamic de novo phosphor-
ylation at S421 in response to membrane depolarizationsuggests that MeCP2 may also function in a novel man-
ner in the nervous system. To gain further insight into
how MeCP2 function might be affected by neuronal ac-
tivity, we used the anti-MeCP2 pS421 antibody to inves-
tigate the regulation of MeCP2 S421 phosphorylation
in cultured neurons.
When cortical neurons were membrane depolarized
for different periods of time using elevated levels of ex-
tracellular potassium to activate L-type voltage-sensi-
tive calcium channels (L-VSCCs), MeCP2 S421 phos-
phorylation could be detected as early as 5 min after
depolarization and reached its maximal level 60 min af-
ter stimulation (Figures 2A–2C). The relatively slow ki-
netics of MeCP2 S421 phosphorylation contrast with
that of other phosphorylation events induced by mem-
brane depolarization, such as the phosphorylation of
CREB at S133, which is maximally activated just minutes
after membrane depolarization (Figure 2A; Kornhauser
et al., 2002). The slow kinetics of activity-dependent
Neuron
258Figure 2. Characterization of S421 as a Site
of Activity-Dependent Phosphorylation on
MeCP2
(A–C) Kinetics of MeCP2 S421 phosphoryla-
tion and dephosphorylation. Lysates were
prepared from rat E18 + 5 DIV cortical neu-
rons membrane depolarized for the indicated
times (A and B) or membrane depolarized for
30 min and repolarized with culture medium
for the indicated times (C).
(D–F) MeCP2 is phosphorylated at S421 in re-
sponse to glutamate (D), NMDA (E), and bicu-
culline (F) in a calcium-dependent manner.
Antitotal MeCP2 and anti-MeCP2 pS421
western blots of extracts from E18 + 12 DIV
hippocampal neurons (D and E) or P1 + 12
DIV hippocampal neurons (F) treated for 1 hr
with the indicated stimuli after a 1 hr pretreat-
ment with the indicated blockers. Nimo,
nimodipine.
(G) MeCP2 S421 phosphorylation is triggered
by neurotrophins. Western blot analysis of
whole-cell extracts prepared from E18 +
12 DIV hippocampal neurons stimulated for
1 hr with BDNF, CNTF, EGF, IGF, NGF, NT3,
NT4, or PDGF.MeCP2 S421 phosphorylation correlates with the rela-
tively slow induction of a subset of activity-regulated
genes such as Bdnf, Narp, Ves1/Homer1a, and Crem/
Icer (Lanahan and Worley, 1998), suggesting that the
phosphorylation of MeCP2 at S421 may be a critical
step in the activation of this class of genes.
Glutamate or NMDA stimulation of cultured hippo-
campal neurons also induced the phosphorylation of
MeCP2 at S421 (Figures 2D and 2E), indicating that stim-
ulation of ligand-gated ion channels that mediate excit-
atory neurotransmission could also trigger MeCP2
phosphorylation at S421. Since both synaptic and extra-
synaptic pools of glutamate receptors can potentially be
activated by bath application of glutamate or NMDA
(Hardingham et al., 2002), we also treated hippocampal
neurons with the GABAA-receptor antagonist bicucul-
line to derepress tonic inhibition of endogenous excit-
atory neurotransmission and selectively allow glutamate
release at synapses (Hardingham et al., 2002). We found
that bicuculline stimulation also induces the phosphory-
lation of MeCP2 at S421 (Figure 2F). This event was de-
pendent in part on activation of NMDA receptors, AMPA
receptors, and L-VSCCs, as antagonists of each of these
channels partially blocked the response (Figure 2F).
Thus, endogenous glutamate release at synapses trig-
gers the phosphorylation of MeCP2 at S421 directly via
the gating of calcium influx through NMDA-type recep-tors and/or indirectly due to glutamate-mediated rises
in membrane potential that activate calcium flux through
L-VSCCs.
We next investigated the range of stimuli that induce
the phosphorylation of MeCP2 at S421 in neurons. We
found that the neurotrophins BDNF, NT3, and NT4 in-
duced the acute phosphorylation of MeCP2 at S421,
whereas CNTF, EGF, IGF, NGF, and PDGF each had
no effect on MeCP2 S421 phosphorylation, even though
these growth factors induced Akt and/or MAPK activa-
tion (Figure 2G). The ability of neurotrophins to induce
MeCP2 S421 phosphorylation appears to be develop-
mentally regulated and present primarily in older neu-
rons (12 DIV), since no effect of neurotrophin treat-
ment on MeCP2 S421 phosphorylation is observed
in younger cultures (Chen et al., 2003). These results
demonstrate that, among the many growth factors
tested, only neurotrophins trigger the phosphorylation
of MeCP2 at S421 in neurons and suggest that neurotro-
phin signaling may regulate MeCP2 function in addition
to or in cooperation with neuronal activity.
Synaptic Activity Driven by Sensory Experience
Induces Acute Phosphorylation of MeCP2 S421
in the Intact Brain
We next examined whether MeCP2 is phosphorylated at
S421 in the brains of intact animals in response to
Activity-Dependent Regulation of MeCP2
259synaptic activity. We first asked if synchronized synaptic
activity induced by chemoconvulsants triggers MeCP2
S421 phosphorylation in the brain. Seizures were in-
duced in rats or mice by intraperitoneal injection of me-
trazole (pentylenetetrazole) or kainic acid, respectively,
and brain extracts or histological sections, respectively,
were prepared from the cortex and hippocampus of
seized and saline-injected control animals. Western
blotting revealed that metrazole-based seizures induced
a significant increase in the levels of S421-phosphory-
lated MeCP2 in the rat brain compared to saline-injected
controls (Figure 3A). Furthermore, immunohistochem-
istry with the anti-MeCP2 pS421 antibody detected
a significant increase in the number of neuronal nuclei
immunopositive for S421-phosphorylated MeCP2 in
cortical layers II–VI and in all regions of the hippocam-
pus of seized brains (Figure 3B and data not shown).
Parallel immunostaining with an antibody that recog-
nizes MeCP2 regardless of its phosphorylation state
(antitotal MeCP2) showed no significant change in the
level of MeCP2 in response to seizures (Figure 3B), sug-
gesting that, in the intact brain, neuronal activity triggers
the phosphorylation of preexisting MeCP2. To confirm
the specificity of the anti-MeCP2 pS421 and antitotal
MeCP2 antibodies for immunohistochemistry, we stained
brain sections from pairs of Mecp22/y null mice left
untreated or stimulated with kainic acid injection and
observed no signal with either antibody under either
condition (Figure 3B, top). Together, these findings
indicate that pharmacologically induced increases in
synaptic activity trigger the acute phosphorylation of
MeCP2 at S421 within neuronal nuclei in the intact brain.
We next asked whether neural activity driven by
a physiologically relevant environmental stimulus in-
duces the phosphorylation of MeCP2 at S421. To obtain
the synchronous activation of a specific population of
neurons, we examined light entrainment of circadian
rhythms, a process that, in mammals, is regulated by
a central pacemaker residing in the suprachiasmatic nu-
clei (SCN) of the hypothalamus (Reppert and Weaver,
2001). Light in the context of the day-night cycle serves
as an important external sensory stimulus to synchro-
nize the near 24 hr internal biological clock to the ex-
ternal 24 hr cycle. Mice that have been entrained to a
12 hr:12 hr light-dark cycle for several days will maintain
a circadian rhythm for many more days, as measured
by locomotor activity during the subjective night, even
when the animals are kept in continuous darkness. Ex-
posure of entrained mice to light during the subjective
night triggers a behavioral shift in the phase of the circa-
dian rhythm that is believed to be mediated by a subset
of retinal ganglion cells that project directly to the SCN,
releasing glutamate onto SCN neurons (Reppert and
Weaver, 2001). This synaptic release of glutamate trig-
gers NMDA receptor-mediated calcium influx, leading
to the induction of CREB S133 and S142 phosphoryla-
tion and the activation of immediate early genes, such
as c-fos or jun-B, within SCN neurons (Kornhauser
et al., 1996).
We investigated whether phosphorylation of MeCP2
at S421 is induced in the SCN by such a light stimulus
that triggers a shift in circadian rhythm. Circadian-
entrained adult mice were transferred to constant dark-
ness for 48 hr and then were either kept in darkness(DD), or exposed during subjective night to a light pulse
of 2, 4, or 6 hr (LP2, LP4, LP6), a stimulus previously
shown to be sufficient to trigger a behavioral shift in
circadian rhythm (Reppert and Weaver, 2001). Tissue
sections were then prepared from the SCN and stained
with the anti-MeCP2 pS421 or antitotal MeCP2 anti-
body. We found that a 2, 4, or 6 hr light pulse induced
a significant increase in the levels of MeCP2 S421 phos-
phorylation in the SCN (Figure 3C, right), whereas only
background staining was observed in the SCN of DD
animals that received no light pulse (Figure 3C, top).
Staining of adjacent sections with the total-MeCP2 anti-
body showed that MeCP2 protein is well expressed in
the SCN, even in DD animals (Figure 3C, left) and that
the overall level of MeCP2 is not significantly affected
by light stimulation. Taken together, these results dem-
onstrate that light, a physiologically and behaviorally
important cue, triggers the de novo phosphorylation of
MeCP2 at S421 in the intact brain.
MeCP2 Is Phosphorylated at S421
Selectively in the Brain
MeCP2 is ubiquitously expressed in mammalian tissues.
Indeed, its widespread expression has been puzzling,
given the predominantly neurological phenotype of
RTT (Zoghbi, 2003). To assess the presence of MeCP2
S421 phosphorylation in various mammalian tissues,
we homogenized equal wet masses of different adult
mouse tissues directly into SDS sample buffer and mea-
sured the level of MeCP2 S421 phosphorylation by west-
ern blotting. Among the 12 different tissue lysates tested
in this experiment, S421-phosphorylated MeCP2 was
detected only in brain lysate, even though, consistent
with previous reports, total MeCP2 protein was present
in many tissues (Figure 4). The lack of MeCP2 S421
phosphorylation in most tissues was not likely due to
dephosphorylation during extract preparation since (1)
the tissues were lysed rapidly in SDS sample buffer
and (2) the phosphorylation of CREB S133 and p42/44
MAPK was observed in most tissues (Figure 4 and
data not shown). In addition, serum or growth-factor
stimulation of a fibroblast cell line (3T3) failed to induce
MeCP2 phosphorylation at S421, although these stimuli
are known to induce the release of calcium from internal
stores and effectively induced CREB (S133) and/or Akt
(S473) phosphorylation (data not shown). These findings
suggest that MeCP2 is selectively phosphorylated at
S421 in neural tissues and raise the possibility that
MeCP2 phosphorylation at S421 may have a specialized
function in the brain. Thus, further investigation into the
functional significance of MeCP2 S421 phosphorylation
may provide insight into the specific role of MeCP2
in the brain and how mutations in MeCP2 lead to the
neurological outcome in RTT.
Phosphorylation of MeCP2 at S421 Regulates
Neuronal Activity-Dependent Gene Expression
We next investigated the significance of S421 phos-
phorylation for MeCP2 function. Our previous studies
suggested that MeCP2 may act as a transcriptional
repressor that must be modified by activity-dependent
phosphorylation if activity-dependent gene activation
is to occur (Chen et al., 2003). To test this hypothesis,
we asked whether the phosphorylation of MeCP2 at
Neuron
260Figure 3. Phosphorylation of MeCP2 at S421 Is Triggered by Synaptic Activity in the Intact Brain
(A) Whole-cell lysates were prepared from P19 rat brains 0, 10, or 30 min after metrazole-based seizure induction and incubated with antibodies
specific to MeCP2 pS421, total MeCP2, pCREB (S133), or total CREB.
(B) Fluorescent immunohistochemistry of coronal cryosections from mouse parietal cortex collected from wild-type (WT) orMecp22/y (KO) mice
3 hr after kainic acid-based seizure induction using antibodies specific for MeCP2 pS421 or total MeCP2. Sections were counterstained with the
nuclear dye Hoechst 33342.
(C) Light exposure during subjective night induces the phosphorylation of MeCP2 S421 in the suprachiasmatic nucleus (SCN). Wild-type mice
were entrained to a 12hr:12hr light-dark cycle and then transferred to constant darkness. Two days later, entrained mice were either maintained
in darkness (DD) or exposed to light for 2, 4, or 6 hr (LP2, LP4, LP6). Adjacent cryosections were alternately immunostained with antibodies
specific for MeCP2 pS421 or total MeCP2.
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activity-dependent gene expression, focusing on Bdnf
promoter IV transcription, a well-characterized model
for activity-dependent gene expression (West et al.,
2002) and a putative target of MeCP2-mediated repres-
sion (Chen et al., 2003).
Since MeCP2 normally binds methylated DNA that is
assembled into chromatin, we assessed the ability of
wild-type and S421A mutant MeCP2 to regulate activ-
ity-dependent transcription at endogenous loci, rather
than to assess their effect on a plasmid-based reporter
gene that, when transfected into cells, might not acquire
a higher-order chromatin conformation. We developed
a lentivirus-mediated protein-replacement assay (LEM-
PRA) that allowed us to substitute endogenous MeCP2
with tagged MeCP2 variants of choice in a high percent-
age of neurons in a culture. A lentiviral vector was used
to deliver a short-hairpin RNA (shRNA) to knock down
endogenous MeCP2 and to express a FLAG-tagged,
shRNA-resistant version of MeCP2 in greater than
90% of neurons in postmitotic hippocampal cultures
(Figure 5A). Lentiviral infection of hippocampal neurons
with this MeCP2 replacement vector resulted in a signif-
icant reduction in the level of endogenous MeCP2
(Figure 5B), along with the stable overexpression of
FLAG-tagged MeCP2 at levels approximately 5-fold
higher than that of normal endogenous MeCP2 (Figures
5B and 5C). Western blotting with the anti-FLAG and
anti-MeCP2 pS421 antibodies revealed that membrane
depolarization of lentiviral-infected neurons expressing
FLAG-MeCP2, but not FLAG-S421A MeCP2, triggered
phosphorylation at S421 (Figure 5C). This result demon-
strates that reconstituted MeCP2 is phosphorylated
in response to neuronal activity.
To determine if the phosphorylation of MeCP2 at S421
affects activity-dependent gene induction, lentiviral-in-
fected neurons expressing either reconstituted FLAG-
tagged wild-type or S421A mutant MeCP2 were left
untreated or membrane depolarized, and the resulting
Figure 4. MeCP2 Is Phosphorylated at S421 Specifically in the Brain
Western analysis of whole-cell lysates prepared from different mam-
malian tissues using antibodies specific to total MeCP2, MeCP2
pS421, and pCREB (S133). Fresh tissues were collected from a 4-
week-old male mouse, directly homogenized into 1.5% SDS sample
buffer at a ratio of 50 mg/ml w:v, and separated on a 12% SDS-PAGE
gel. The same blot was reprobed with an anti-GAPDH antibody as an
indicator of sample loading.level of Bdnf exon IV transcripts was assessed by quan-
titative RT-PCR. WhereasBdnf exon IV induction in neu-
rons that expressed wild-type MeCP2 is similar to that
seen in control-infected cultures, activity-dependent
Bdnf exon IV induction is significantly impaired in neu-
rons expressing S421A mutant MeCP2 (Figure 5D). This
effect did not reflect the general inhibition of calcium-
dependent signaling pathways because the activity-
dependent transcription of another immediate early
gene, c-fos, is not inhibited in neurons expressing S421A
mutant MeCP2 as compared to wild-type MeCP2 (Fig-
ure 5E). These findings are consistent with the possibil-
ity that the nonphosphorylatable S421A mutant MeCP2
remains bound to the promoters of activity-regulated
genes such as Bdnf and maintains these genes in a
repressed state, even under conditions of membrane
depolarization. In further support of this idea, the S421A
mutant MeCP2 appears to bind methylated DNA with
similar affinity as non-S421-phosphorylated MeCP2 in
vitro (see Figure S1 in the Supplemental Data available
with this article online), and the attenuation of Bdnf
exon IV transcription is not seen with an S421A mutant
MeCP2 bearing an R106W point mutation that abolishes
methyl-DNA binding (data not shown). Taken together,
these findings support a model in which neuronal activ-
ity and subsequent calcium influx relieve MeCP2-
mediated transcriptional repression via phosphorylation
of MeCP2 at S421.
Phosphorylation of MeCP2 at S421 Mediates
Dendritic Patterning and Dendritic Spine
Development
The requirement of MeCP2 S421 phosphorylation for
activity-dependent Bdnf transcription prompted us to
examine whether phosphorylation of MeCP2 at S421 is
important for biological processes known to be regu-
lated by neuronal activity. We investigated the signifi-
cance of MeCP2 S421 phosphorylation for dendritic
patterning and dendritic spine morphogenesis, two
activity-mediated processes that have been linked to
RTT on the basis of neuropathological studies of RTT
individuals and Mecp22/y mutant mice. Given that over-
expression of MeCP2 from duplications ofMECP2 leads
to RTT-like disorder(s), we reasoned that we could
use MeCP2 overexpression as an experimental model
to test the significance of S421 phosphorylation for ac-
tivity-dependent neuronal maturation. We biolistically
transfected organotypic hippocampal slice cultures
with a lentiviral-based plasmid expressing both an
shRNA to knockdown expression of endogenous
MeCP2 and a FLAG-tagged shRNA-resistant version of
MeCP2 (LEMPRA construct, Figures 5A–5C, S3, and
S4C). This construct was used to reduce levels of en-
dogenous MeCP2 protein, increasing the probability
that exogenously introduced MeCP2 would efficiently
replace endogenous MeCP2 that is complexed into
chromatin. We also cotransfected another dual-pro-
moter vector that expresses an eGFP reporter and the
antiapoptotic protein Bcl-XL. Bcl-XL was introduced to
minimize the possibility that any effects we observed
on dendrites were secondary to an effect of MeCP2
knockdown or overexpression on survival. Whereas
Bcl-XL is known to inhibit cell death, it does not affect
dendritic arborization (Gaudilliere et al., 2004).
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Is Required for Activity-Induced Induction of
Bdnf Transcription
(A) The lentivirus-mediated protein-replace-
ment assay (LEMPRA) construct contains
two expression cassettes: (1) the pU6 pol III
promoter directing the expression of an
shRNA directed against endogenous MeCP2
and (2) the human Ubiquitin-C promoter driv-
ing the expression of a bicistronic cassette
comprised of FLAG-tagged shRNA-resistant
wild-type or S421A mutant MeCP2 followed
by an internal ribosomal entry site (IRES)
directing GFP expression. When packaged
into and delivered by a lentivirus, the con-
struct is effective in replacing MeCP2 in
greater than 90% of neurons in a culture.
(B and C) LEMPRA can effectively reduce en-
dogenous MeCP2 and express functional
FLAG-tagged MeCP2 variants of choice.
E18 rat hippocampal neurons were infected
at 1 DIV with indicated lentiviruses. Extracts
were prepared at 4 DIV (B) or 7 DIV (C) and
incubated with antibodies specific to FLAG,
MeCP2 pS421, or total MeCP2. shRNA, small
hairpin RNA against MeCP2; sr-FgMP2,
FLAG-tagged shRNA-resistant mouse MeCP2,
e2 form; scr shRNA, scrambled shRNA;
rMeCP2, endogenous rat MeCP2. Note that
in (C), 5-fold more control lysates were
loaded than wild-type or S421A-MeCP2
lysates for comparison of expression levels.
(D and E) E18 + 1 DIV hippocampal neurons
were infected with control, wild-type, or
S421A mutant MeCP2 LEMPRA lentiviruses.
Total RNA was collected at 7 DIV from in-
fected neurons that were either left untreated (2) or membrane depolarized with 55 mM KCl for 3 hr (+). Bdnf exon IV (D) and c-fos (E) mRNA
levels were measured by quantitative RT-PCR and normalized to aGapdh control (data are mean6SEM; *p < 0.01, Bonferroni-corrected multiple
comparison after ANOVA). Note that the nomenclature for the exons of the Bdnf gene has changed due to the identification of additional Bdnf
transcripts in rodent; Bdnf exon IV was previously known as Bdnf exon III, for example, in Chen et al. [2003]).Dendritic branching was quantified using Sholl analy-
sis, a method which reports the number of intersections
between the dendritic arbor and a series of concentric
circles of increasing radii centered at the cell body
(see Supplemental Experimental Procedures). We found
that replacement of endogenous MeCP2 with FLAG-
tagged wild-type MeCP2 in hippocampal pyramidal
neurons resulted in a significant decrease in dendritic
branch complexity as compared to a vector control
(p < 0.05, n = 45–51/condition; Figures 6A and 6D).
This effect on dendritic branching reflects the overex-
pression of MeCP2 (Figures S3–S5) and may be relevant
to recent reports that transgenic mouse models that
overexpress MeCP2 and individuals with a duplication
of the MeCP2 locus develop a RTT-like, progressive
neurological disorder (see Introduction). Consistent
with previous reports in Mecp22/y null mice and RTT
brains, we also observed a simplification in the dendritic
arbors of hippocampal pyramidal neurons transfected
only with the shRNA directed against MeCP2, as com-
pared to the vector control (p < 0.05, n = 25/condition;
Figures 6A and 6C). Efficient knockdown of MeCP2
protein by the shRNA construct was confirmed by
immunostaining (Figures S3 and S4). Taken together,
these results indicate that the development of appropri-
ate dendritic morphology requires a precise set point
of MeCP2 expression; either the elimination of MeCP2or the overexpression of MeCP2 leads to a decrease
in dendritic arbor complexity.
In contrast to the effect of wild-type MeCP2 expres-
sion on dendritic complexity, expression of the S421A
mutant MeCP2 in hippocampal pyramidal neurons had
no significant effect on dendritic branch complexity rel-
ative to vector control (p = 0.14; n = 45–51/condition;
Figures 6A and 6D). This finding indicates that the muta-
tion of MeCP2 S421 to an alanine blocks the ability of
MeCP2 overexpression to restrict dendritic growth.
Importantly, we confirmed that exogenously expressed
FLAG-tagged wild-type and S421A mutant MeCP2
are localized to the nucleus (Figures 6A, S3, and S5)
and are expressed at similar levels, demonstrated by
quantification of either anti-FLAG or antitotal MeCP2 im-
munostaining intensity (Figures S4B and S4C and S5).
Quantification of antitotal MeCP2 immunostaining also
revealed that FLAG-tagged wild-type or S421A-MeCP2
are overexpressed approximately 4-fold in transfected
neurons compared to endogenous MeCP2 levels in ei-
ther untreated or control-transfected cells (Figure S4C).
Furthermore, exogenously expressed wild-type MeCP2,
but not S421A mutant MeCP2, is efficiently phosphory-
lated at S421 in response to conditions of membrane
depolarization or glutamate stimulation (Figure S5 and
data not shown). Finally, to eliminate the possibility that
the observed changes in dendritic branch complexity
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(A) Organotypic hippocampal slices were prepared from P5–7 rat pups and biolistically transfected after 2 days in culture with LEMPRA-based
plasmid DNA encoding a control vector (in which the shRNA directed against MeCP2 is replaced with a scrambled shRNA and a stop codon
is introduced directly after the FLAG epitope), the anti-MeCP2 shRNA only, wild-type MeCP2, or S421A MeCP2, in combination with a dual-
promoter plasmid expressing eGFP and Bcl-XL. Representative 253 images of 7 DIV transfected pyramidal neurons are shown. Scale bar,
50 mm. Pseudocoloring: green, GFP; red, anti-FLAG; blue, antitotal MeCP2.
(B) Representative 633 GFP images of dendritic spines from control-, anti-MeCP2 shRNA-, wild-type MeCP2-, or S421A MeCP2-transfected
neurons. Scale bar, 2 mm.
(C and D) Quantification of dendritic branch complexity by Sholl analysis (data are presented as mean 6 SEM, *p < 0.05, ANOVA).
(E and F) shRNA-mediated knockdown of MeCP2 does not affect dendritic spine morphology (p > 0.05, K-S test)
(G and H) Quantification of the effects of wild-type or S421A mutant MeCP2 overexpression on dendritic spine length (G) and width (H) (p < 0.05
for wild-type versus S421A or wild-type versus control, K-S test).reflect differences in neuronal viability and/or relative
levels of GFP expression, we quantified the average in-
tensity of GFP signal in dendrites lying within the Shollradius of analysis and found no significant differences
in the level of dendritic GFP among neurons transfected
with wild-type, S421A mutant MeCP2, or vector control
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the phosphorylation of MeCP2 at S421 regulates the
inhibition of dendritic growth mediated by MeCP2 over-
expression.
Although RTT has been suggested to be a conse-
quence of the disruption of experience-dependent syn-
aptic development and refinement (Zoghbi, 2003), it has
not been established how neuronal activity acting
through MeCP2 might regulate synaptic maturation.
We therefore tested the effect of mutating MeCP2 at
its site of activity-dependent phosphorylation (S421)
on the development of dendritic spines, the major sites
of excitatory synaptic transmission onto neurons that
are thought to be morphological correlates of synaptic
contacts (Nimchinsky et al., 2002). Using the experimen-
tal paradigm described above, we observed a similar
density of spines studding the dendrites of neurons in
which endogenous MeCP2 was replaced with either
FLAG-tagged wild-type or S421A mutant MeCP2 (Fig-
ure S2); however, we found that spines of neurons over-
expressing wild-type MeCP2 were on average longer,
thinner, and more filopodia-like than spines of control
neurons or neurons transfected with the S421A mutant
MeCP2 (p < 0.05, n = 29–35 cells and 9,561–11,553
spines; Figures 6B, 6G, and 6H), resembling immature
spines. These results indicate that, although wild-type
or S421A mutant MeCP2 expression does not appear
to effect the formation or maintenance of spines, the
overexpression of wild-type MeCP2 retards the matura-
tion of dendritic spines in an S421 phosphorylation-de-
pendent manner. Interestingly, transfection of only the
shRNA directed against MeCP2 had no effect on either
dendritic spine density or morphology (n = 25 cells and
7425–8668 spines; Figures S2, 6B, 6E, and 6F), although
immunostaining for total MeCP2 indicated efficient
knockdown of MeCP2 protein levels (Figures S3 and
S4C). These data indicate that MeCP2 overexpression
results in a distinct but overlapping set of phenotypes
compared to MeCP2 loss of function—overexpression
of MeCP2 affects dendritic patterning and dendritic
spine morphology, whereas the reduction of MeCP2 ex-
pression by RNA interference affects dendritic pattern-
ing, but not dendritic spine morphology. These results
suggest that the phosphorylation of MeCP2 at S421 by
neuronal activity plays a key role in regulating the func-
tion of MeCP2 in mediating dendritic patterning and
dendritic spine maturation.
CaMKII Mediates the Activity-Dependent
Phosphorylation of MeCP2 at S421 in Neurons
To gain further insight into the mechanisms regulating
activity-dependent MeCP2 phosphorylation and func-
tion, we investigated the signaling pathways by which
activity-mediated calcium influx regulates MeCP2
S421 phosphorylation in neurons. To identify the ki-
nase(s) that phosphorylate MeCP2 at S421, cortical neu-
rons were incubated with a variety of kinase inhibitors,
membrane depolarized with elevated levels of extracel-
lular potassium or stimulated with NMDA, and assessed
for the induction of MeCP2 S421 phosphorylation.
Whereas pretreatment with pharmacological inhibitors
of CaMKK, PKA, PKC, MAPK, CDK5, or PI3K each has no
effect on membrane depolarization-dependent MeCP2
S421 phosphorylation (data not shown), the CaMKIIinhibitor KN-93, but not its inactive analog KN-92, effec-
tively blocks the membrane depolarization-induced
phosphorylation of MeCP2 at S421 (Figures 7A and
7B). We also blocked CaMKII activity using CaMKIIN,
a potent and specific endogenous protein inhibitor of
CaMKII (Chang et al., 1998). Coexpression of CaMKIIN
with FLAG-MeCP2 in cortical neurons blocks the ability
of membrane depolarization to trigger MeCP2 S421
phosphorylation (Figure 7C). This effect was specific to
CaMKII because coexpression of dominant negative
versions of other CaMK family members (dn-CaMKI,
dn-CaMKIV, or dn-CaMKK) with FLAG-MeCP2 had no
effect (Figure 7C and data not shown).
We also found that increasing CaMKII activity pro-
motes the phosphorylation of MeCP2 at S421 in neurons
or HEK 293T cells. Anti-FLAG western blots of extracts
from neurons or HEK 293T cells that coexpress con-
stitutively active CaMKII (ca-CaMKII) and FLAG-
MeCP2 revealed the presence of the slow-migrating,
phosphorylated form of MeCP2, even in the absence
of membrane depolarization (Figures 7C and 7D).
However, coexpression of ca-CaMKK, ca-CaMKI, or
ca-CaMKIV with FLAG-MeCP2 had no effect on the
phosphorylation status of MeCP2 S421 in unstimulated
neurons or HEK 293T cells (Figures 7C and 7D and
data not shown). Altogether, these results suggest that
CaMKII mediates the phosphorylation of MeCP2 at
S421 in response to neuronal activity-induced calcium
influx.
We also tested whether MeCP2 is a direct substrate of
CaMKII in vitro. Wild-type, S421A mutant, or C5A mutant
forms of FLAG-tagged MeCP2 were purified from HEK
293T cells and analyzed in an in vitro kinase assay for
their ability to be phosphorylated by recombinant, con-
stitutively active CaMKII. The C5A mutant bears alanine
mutations at S341, S350, S360, S385, and S399 in
MeCP2. Recombinant CaMKII efficiently phosphory-
lates wild-type or C5A mutant MeCP2 in vitro, indicated
by the appearance of the 32P-ATP-labeled, slow-migrat-
ing form of MeCP2 (Figure 7E, left). By contrast, signifi-
cantly less phosphorylated MeCP2 was observed when
S421A mutant MeCP2 was incubated with CaMKII
(Figure 7E, left) or when wild-type MeCP2 was incubated
with CaMKI, CaMKIV, or in the absence of recombinant
kinase (data not shown, and Figure 7E, right). The resid-
ual background labeling observed was likely due to co-
purification of endogenous kinase(s) from the HEK 293T
cell extract since this level of phosphorylation was de-
tected in the absence of the addition of CaMKII. These
results indicate that CaMKII, in contrast to many other
kinases, phosphorylates MeCP2 in vitro in an S421-de-
pendent manner. Taken together, these findings sup-
port a model in which CaMKII mediates the neural-spe-
cific phosphorylation of MeCP2 at S421 in response to
synaptic activation and subsequent calcium influx.
Whether MeCP2 S421 is a direct substrate of CaMKII
in vivo or whether CaMKII acts through as-yet-unidenti-
fied intermediaries to mediate MeCP2 S421 phosphory-
lation remains an open question. Interestingly, KN93
pretreatment of hippocampal neurons also blocks the
BDNF-dependent induction of MeCP2 S421 phosphory-
lation (Figure 7F), suggesting that CaMKII may also me-
diate the phosphorylation of MeCP2 at S421 in response
to neurotrophin signaling.
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tion of MeCP2 at S421
(A and B) Western blot analysis of extracts
from E18 + 10 DIV hippocampal neurons
that were pretreated for 60 min with the
CaMKII inhibitor KN93, the inactive analog
KN92, or vehicle control (DMSO), followed
by stimulation with 55 mM KCl (A) or 20 mM
NMDA (B) for 30 min.
(C) E18 + 5 DIV cortical neurons were cotrans-
fected with FLAG-tagged MeCP2 and vector
control, ca-CaMKK, dn-CaMKK, ca-CaMKII,
or CaMKII-N. Extracts were prepared from
these neurons left unstimulated (2) or mem-
brane depolarized for 1 hr (+) 2 days after
transfection and probed with antibodies spe-
cific to the FLAG epitope. ca, constitutive-
active; dn, dominant-negative.
(D) Western blot analysis using anti-MeCP2
pS421 or anti-FLAG antibodies of extracts
from HEK293T cells cotransfected with
FLAG-MeCP2 and vector control, ca-CaMKI,
ca-CaMKII, ca-CaMKIV, or ca-Akt.
(E) CaMKII phosphorylates MeCP2 in vitro.
FLAG-tagged wild-type, S421A mutant
MeCP2, or C5A mutant MeCP2 (S341A,
S350A, S360A, S385A, S399A) were purified
from HEK293T cells, coincubated with re-
combinant constitutively active CaMKII (left
panel) and 32P-ATP, and separated on an
SDS-PAGE gel. The right panel shows the re-
sults of a control reaction in the absence of
any added kinase.
(F) BDNF-dependent induction of MeCP2
S421 phosphorylation is likely mediated by
CaMKII. Western blot analysis of whole-cell
extracts prepared from E18 + 12 DIV hippo-
campal neurons that were treated with indi-
cated agents for 60 min followed by BDNF
treatment for 60 min. K252a is an inhibitor of
the BDNF receptor TrkB.Discussion
In this study, we identify an important missing link in the
synaptic hypothesis of RTT by identifying S421 as a ma-
jor site of activity-dependent modification on MeCP2
that is required for the maturation of neuronal connectiv-
ity, thereby providing a potential mechanism by which
experience-dependent stimuli might regulate MeCP2
function. Using a phospho-site-specific antibody, we
demonstrate that neuronal activity and subsequent cal-
cium influx induces the de novo phosphorylation of
MeCP2 at S421 in neurons in vitro and in vivo. For exam-
ple, physiological light stimulation that regulates circa-
dian behavior triggers the phosphorylation of MeCP2
at S421 in the intact brain. Importantly, we show that,
although MeCP2 is expressed throughout the body,
it appears to be phosphorylated at S421 selectively
in the brain by a CaMKII-dependent mechanism. The
phosphorylation of MeCP2 at S421 is required for
MeCP2-dependent regulation of dendritic patterning,
spine morphogenesis, and activity-dependent gene
expression (Figure 8). These findings suggest a key
role for the activity-dependent regulation of MeCP2 in
the maturation of neuronal connectivity and provide
a new framework for understanding how mutations in
MeCP2 lead to the deregulation of these processes
in RTT.In addition to providing insight into the role of neuro-
nal activity in regulating MeCP2 function, our study high-
lights the importance of exact MeCP2 expression levels
in mediating neuronal development and to RTT. Al-
though MeCP2 overexpression phenocopies a loss of
function in MeCP2 in several aspects, such as a reduc-
tion in dendritic arbor complexity and reduced soma
size (data not shown), MeCP2 overexpression also
causes distinct phenotypes not seen in the loss of func-
tion, such as a delay in dendritic spine maturation. These
findings provide clues as to how overexpression of
MeCP2 leads to neurological abnormalities, a question
of considerable interest given recent reports that dupli-
cations of theMECP2 locus may be the genetic basis for
a subset of cases of RTT-like syndromes (Ariani et al.,
2004; Lugtenberg et al., 2006; Meins et al., 2005; Van
Esch et al., 2005).
Accruing evidence suggests that deregulation of the
activity-responsive gene Bdnf may play a central role in
RTT. Our finding that both MeCP2 S421 phosphorylation
regulates the activity-dependent induction of Bdnf tran-
scription and that BDNF treatment triggers MeCP2 S421
phosphorylation suggests that a complex set of interac-
tions between MeCP2 and BDNF coregulates their func-
tions.Mecp22/y andBdnf2/2 knockout mice share many
overlapping phenotypes, which include smaller brain
size, reduced dendritic arbor complexity, impaired
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genesis and Spine Maturation by Activity-
Dependent Phosphorylation of MeCP2presynaptic function and synaptic plasticity, and limb
clasping (Chang et al., 2006; Gorski et al., 2003; Korte
et al., 1995; Patterson et al., 1996), consistent with
reports that BDNF protein and transcript levels are
reduced in Mecp22/y null brains (Chang et al., 2006).
Although our model posits that activity- or neurotro-
phin-dependent MeCP2 S421 phosphorylation relieves
its transcriptional repressor function on Bdnf promoter
IV and would predict an increase in BDNF levels in
Mecp22/y null mice, the decreased levels of the activ-
ity-dependent gene product BDNF that are observed in
vivo may be secondary to reduced cortical activity in
Mecp22/y null brains (Chang et al., 2006; Dani et al.,
2005).
Consistent with the hypothesis that MeCP2 S421
phosphorylation is required for activity-dependent acti-
vation of Bdnf promoter IV, we found that overexpres-
sion of S421A mutant MeCP2 inhibits the induction of
Bdnf exon IV in response to membrane depolarization
and that this inhibition is dependent on DNA binding.
This result is consistent with our findings that phosphor-
ylation of MeCP2 correlates with a reduced ability of
MeCP2 to bind methylated DNA and Bdnf promoter IV
(Figure S1; Chen et al., 2003). Taken together, these
observations suggest that, in the absence of neuronal
activity, MeCP2 binds to the promoters of activity-
regulated genes such as Bdnf and represses their tran-
scription. In the context of synaptic activity, membranedepolarization triggers the phosphorylation of MeCP2
at S421, leading to reduced binding of MeCP2 to Bdnf
promoter IV and a relief of transcriptional repression,
allowing for full gene activation that is mediated by the
calcium-dependent modification of a host of transcrip-
tional activators such as CREB, CaRF, and USFs
(West et al., 2002).
Our finding that the S421A mutant of MeCP2 sup-
presses the activity-dependent transcription of Bdnf
provides a possible explanation for the differential ef-
fects of wild-type and S421 mutant MeCP2 on dendrite
and spine morphogenesis. When compared to overex-
pressed S421A mutant MeCP2, overexpressed wild-
type MeCP2 may promote the induction of a variety of
activity-responsive genes that regulate neuronal con-
nectivity. Although it might seem counterintuitive that
the higher levels of BDNF in neurons overexpressing
wild-type MeCP2, compared to S421 mutant MeCP2,
would contribute to the inhibition of dendritic growth
and spine maturation, the effects of BDNF have been
shown to be highly context dependent (Poo, 2001). For
instance, BDNF has been shown to inhibit basal den-
dritic complexity of layer VI cortical pyramidal neurons
in culture (McAllister et al., 1995) and to inhibit dendritic
branching in Xenopus retinal ganglion cells in vivo (Lom
and Cohen-Cory, 1999). In addition, MeCP2 has many
other transcriptional target genes besides Bdnf, among
them Dlx5, Ube3a, Sgk1, and Fkbp5 (Bienvenu and
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of MeCP2 overexpression on neuronal development
might also reflect the deregulation of one or several
yet-to-be-discovered target genes.
An important unresolved question is how phosphory-
lation of MeCP2 at S421, a site near the C terminus of
MeCP2 that is remote from the DNA binding domain of
MeCP2, disrupts the ability of MeCP2 to repress activ-
ity-responsive promoters such as Bdnf promoter IV.
One possibility is that phosphorylation of MeCP2 at
S421 triggers a conformational change in MeCP2 that re-
duces its binding affinity for methyl-DNA sequences. Al-
ternatively or in addition, activity-mediated S421 phos-
phorylation may serve as a priming event to allow
additional modifications of MeCP2, perhaps on residues
within the DNA binding domain itself that might alter DNA
binding affinity. Interestingly, our mass spectrometry
analysis of MeCP2 purified from neuronal extracts
revealed two additional sites of phosphorylation on
MeCP2 at S80 and S229. Whether S80 and S229 are
also responsive to neuronal activity, and whether S421,
S80, S229, or other still unknown sites of modification
are coordinately modified to regulate the function of
MeCP2 in activity-dependent gene expression warrants
further investigation.
Our finding that CaMKII mediates the phosphorylation
of MeCP2 at S421 may be relevant to the well-known
role of CaMKII and other CaMK family members in neu-
rite extension and dendritic patterning (Gaudilliere et al.,
2004; Redmond et al., 2002; Shen et al., 1998; Wayman
et al., 2006). The implication of CaMKII in the regulation
of MeCP2 function is also intriguing in the context of the
cognitive deficits observed in RTT because a large body
of literature indicates that CaMKII plays a critical role in
regulating synaptic development and plasticity (Lisman
et al., 2002). Notably, many of the molecular players in
the calcium-dependent signaling pathway that mediates
neuronal activity-dependent gene expression have now
been shown through human genetics to be important
for the development of cognitive function, including
CAV1.2, CBP, BDNF, and MECP2 (Hong et al., 2005).
Further investigation of the mechanisms mediating
neuronal activity-dependent transcription is likely to
uncover additional factors important for human neural
development.
An incisive way to understand the in vivo biological
importance of MeCP2 S421 phosphorylation for RTT
will be to develop mice that bear a single point mutation
at MeCP2 S421 that converts it to alanine, rendering en-
dogenous MeCP2 S421 refractory to phosphorylation.
This knockin mouse model will allow us to assess the hy-
pothesis that phosphorylation of MeCP2 at S421 is an
important molecular event that regulates adaptive re-
sponses to the environment and to test the idea that
the inappropriate regulation of MeCP2 S421 phosphory-
lation in the brains of individuals with RTT could underlie
some of the neurological symptoms associated with
RTT. For instance, our finding that MeCP2 is rapidly
phosphorylated in the SCN in response to light exposure
suggests that MeCP2 may function in regulating circa-
dian rhythms. Interestingly, sleep disturbances are fre-
quently reported in RTT, and the Mecp2308/y C-terminal
mutant mice have abnormalities in the diurnal regulation
of motor activity (Moretti et al., 2005). It will be interest-ing to examine in more detail whether the activity-de-
pendent phosphorylation of MeCP2 at S421 regulates
sleep-wake behaviors.
Taken together, the evidence to date suggests a model
in which experience-dependent stimuli trigger the dy-
namic modification of MeCP2, thereby modulating its
function as a key transcriptional regulator that controls
the normal developmental maturation of the nervous
system (Figure 8). Thus, MECP2 mutations or duplica-
tions that occur in RTT might disrupt the ability of the
nervous system to appropriately convert activity-
dependent cues into programs of gene expression that
guide the structural and functional maturation of neuro-
nal circuits. Ultimately, the phosphorylation of MeCP2
at S421 may be only one of a number of posttranslational
modifications on MeCP2; however, its selective occur-
rence in the brain suggests that further efforts to eluci-
date the importance of MeCP2 S421 phosphorylation
for brain development and the mechanisms by which
S421 phosphorylation regulates MeCP2 function may
further our understanding of how mutations in MeCP2
lead to the neurological phenotype of RTT.
Experimental Procedures
See Supplemental Experimental Procedures for details of immuno-
histochemistry, imaging, image analysis, seizure induction, circa-
dian entrainment, viral infection, quantitative real-time PCR, protein
purification, kinase assay, and southwestern assay.
Plasmids and Antibodies
The antibodies that recognize either MeCP2 regardless of its phos-
phorylation at S421 (antitotal MeCP2) or S421-phosphorylated
MeCP2 (anti-MeCP2 pS421) were both generated in rabbits using
peptide antigens. MeCP2 expression vectors were constructed us-
ing the mouse e1 form of MeCP2, except where otherwise noted.
See Supplemental Experimental Procedures for further details.
Cell Culture
Dissociated neuronal cultures were prepared and transfected by the
calcium phosphate method as previously described (Xia et al.,
1996). Three hundred fifty micrometer slices of P5–7 rat hippocam-
pus were organotypically cultured as described in Stoppini et al.
(1991) and transfected biolistically. See Supplemental Experimental
Procedures for further details.
Lentiviral Production
Lentiviruses were pseudotyped with the VSV-G envelope and con-
centrated by centrifugation as previously described (Lois et al.,
2002). See Supplemental Experimental Procedures for further
details.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/52/2/255/DC1/.
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